By Adria Calatayud

 

Sanofi said its Tzield drug met the primary goal of a phase 3 clinical trial, showing potential to slow the progression of a type of diabetes in newly diagnosed children and adolescents.

The French pharmaceutical giant said Tzield demonstrated in the trial superior beta-cell preservation compared with placebo, and that this indicates its potential to slow the progression of Stage 3 type 1 diabetes in this population.

The trial studied the efficacy and safety of the drug in children and adolescents aged 8-17 years, the company said.

Results for the study's key secondary goals, which included a numerically lower mean insulin dose, weren't considered statistically significant, Sanofi said.

Sanofi added Tzield to its portfolio through the acquisition of Provention Bio, which was completed in April.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

October 18, 2023 05:25 ET (09:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Sanofi.